Enhancing Capital’s Eli Lilly LLY Stock Holding History

Enhancing Capital’s Portfolio LLY Stock Details LLY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$9.6M	Buy	8,302 +2	+0%	+$2.36K	6.66%	3
2026 Q2	$10M	Hold	8,300	–	–	6.84%	1
2026 Q1	$7.63M	Hold	8,300	–	–	5.66%	2
2025 Q4	$8.92M	Hold	8,300	–	–	6.38%	2
2025 Q3	$6.33M	Hold	8,300	–	–	4.63%	4
2025 Q2	$6.47M	Hold	8,300	–	–	4.93%	3
2025 Q1	$6.86M	Hold	8,300	–	–	5.48%	2
2024 Q4	$6.41M	Buy	+8,300	New	+$6.87M	5.11%	2
2022 Q3	$2.71M	Hold	8,300	–	–	3.35%	5
2022 Q2	$2.69M	Hold	8,300	–	–	3.21%	8
2022 Q1	$2.38M	Hold	8,300	–	–	2.54%	10
2021 Q4	$2.29M	Buy	+8,300	New	+$2.1M	2.49%	12

Other funds holding LLY

Lilly Endowment Indiananapolis, Indiana $104B AUM 51.65% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Old National Bancorp Evansville, Indiana $5.07B AUM 22.07% 1-Year Est. Return

Enhancing Capital's LLY Position: Q3 2026 in Review

Enhancing Capital increased its Eli Lilly (LLY) stake by 0.02% in Q3 2026, buying an estimated $2.36K and bringing the position to 8,302 shares worth $9.6M. The position accounts for 6.66% of the portfolio, ranked #3.

Enhancing Capital first reported a position in LLY in Q4 2021 and has held it in 12 quarters since. The position peaked at $10M in Q2 2026. 1,995 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

Enhancing Capital held 8,302 shares of Eli Lilly worth $9.6M as of Q3 2026.
Enhancing Capital bought 2 Eli Lilly shares in Q3 2026, an estimated $2.36K.
Eli Lilly made up 6.66% of Enhancing Capital's portfolio in Q3 2026, its #3 holding.
Enhancing Capital first reported a position in Eli Lilly in Q4 2021 and has held it in 12 quarters since.
Enhancing Capital's Eli Lilly position peaked at $10M in Q2 2026.
1,995 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Enhancing Capital's 13F filing for Q3 2026, filed 26 Oct 2026.